BridgeBio Pharma Inc at Bank of America Healthcare Conference Transcript
Afternoon session of day 2 of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. It's my pleasure today to introduce Neil Kumar, CEO of BridgeBio.
Neil, would you like to start off with some opening remarks, then we can get into Q&A?
Yes, sure. That would be great. And thank you so much for having us. It's been a wonderful last day here.
Just as a reminder, BridgeBio Pharma is a clinical-stage biotechnology company that focuses on genetic diseases, both precision oncology, as well as Mendelian diseases with some 20-odd programs ranging from Phase III all the way back to preclinical discovery. And as I think most of you in the room know, we had a fairly significant setback at the beginning of this year with our ATTR cardiomyopathy program, Part A. And since then, basically, our strategic posture has been defined by a couple of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |